29,607 Shares in C.R. Bard, Inc. (BCR) Purchased by Stevens Capital Management LP
Stevens Capital Management LP acquired a new position in C.R. Bard, Inc. (NYSE:BCR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 29,607 shares of the medical instruments supplier’s stock, valued at approximately $9,359,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Amalgamated Bank raised its holdings in C.R. Bard by 53.8% in the 2nd quarter. Amalgamated Bank now owns 8,555 shares of the medical instruments supplier’s stock worth $2,704,000 after acquiring an additional 2,993 shares during the last quarter. Bahl & Gaynor Inc. raised its holdings in C.R. Bard by 3.7% in the 2nd quarter. Bahl & Gaynor Inc. now owns 11,316 shares of the medical instruments supplier’s stock worth $2,543,000 after acquiring an additional 399 shares during the last quarter. KCM Investment Advisors LLC raised its holdings in C.R. Bard by 0.5% in the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock worth $691,000 after acquiring an additional 10 shares during the last quarter. Captrust Financial Advisors purchased a new position in C.R. Bard in the 2nd quarter worth approximately $192,000. Finally, Norinchukin Bank The raised its holdings in C.R. Bard by 7.3% in the 2nd quarter. Norinchukin Bank The now owns 5,024 shares of the medical instruments supplier’s stock worth $1,588,000 after acquiring an additional 343 shares during the last quarter. Institutional investors own 79.34% of the company’s stock.
In related news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.80% of the company’s stock.
Shares of C.R. Bard, Inc. (NYSE BCR) traded down 0.29% during midday trading on Friday, hitting $319.57. 393,428 shares of the stock were exchanged. The stock has a market cap of $23.22 billion, a price-to-earnings ratio of 41.95 and a beta of 0.60. The firm’s 50-day moving average is $320.16 and its 200-day moving average is $297.42. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $324.58.
C.R. Bard (NYSE:BCR) last issued its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter last year, the company posted $2.54 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. Equities research analysts predict that C.R. Bard, Inc. will post $11.84 earnings per share for the current year.
A number of equities analysts recently weighed in on BCR shares. BidaskClub lowered shares of C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Monday, June 12th. BMO Capital Markets restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Thursday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the company. C.R. Bard has a consensus rating of “Hold” and a consensus price target of $292.00.
COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/09/17/29607-shares-in-c-r-bard-inc-bcr-purchased-by-stevens-capital-management-lp.html.
C.R. Bard Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.